Are partial PPAR gamma agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney

V. Sharma
{"title":"Are partial PPAR gamma agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney","authors":"V. Sharma","doi":"10.15272/AJBPS.V6I57.822","DOIUrl":null,"url":null,"abstract":"Diabetes mellitus is probably the single most important metabolic disease and is widely recognized as one of the leading causes of death and disability. Up to a third of people with diabetes mellitus suffer end-stage renal failure due to diabetic nephropathy. Diabetic nephropathy strategies to delay progression of diabetic nephropathy- including glycemic and blood pressure control, modification of the rennin-angiotensin system and management of lipid levels with statins-have been effective, but development of new strategies is essential if the ever-increasing burden of this disease is to be minimized. Peroxisome proliferator-activated receptors (PPAR) are members of the nuclear hormone receptor superfamily of ligand- activated transcription factors. PPAR-γ is the key regulator of lipid metabolism and energy balance implicated in the development of insulin resistance. The identification of putative natural and synthetic ligands and activators of PPAR-γ has helped to unravel the molecular basis of its function, including molecular details regarding ligand binding, conformational changes of the receptor and cofactor binding leading to the emergence of the concept of selective PPAR-γ modulators .No satisfactory therapeutic option is currently available to treat patients with nephropathy except for fewer agents like angiotensin converting enzyme inhibitors, angiotensin AT1 receptor blockers and few antioxidants, which have been shown to improve the function of diabetic kidney to some extent. Thus, tremendous efforts are being made to explore promising therapeutic interventions to treat diabetic nephropathy. This review discussed various presently employed and recently developed pharmacological interventions to treat diabetic nephropathy and to improve the function of diabetic kidney. In addition, the recently identified potential target sites involved in the pathogenesis of diabetic nephropathy have been delineated.","PeriodicalId":8517,"journal":{"name":"Asian Journal of Biomedical and Pharmaceutical Sciences","volume":"26 1","pages":"01-03"},"PeriodicalIF":0.0000,"publicationDate":"2016-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Biomedical and Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15272/AJBPS.V6I57.822","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Diabetes mellitus is probably the single most important metabolic disease and is widely recognized as one of the leading causes of death and disability. Up to a third of people with diabetes mellitus suffer end-stage renal failure due to diabetic nephropathy. Diabetic nephropathy strategies to delay progression of diabetic nephropathy- including glycemic and blood pressure control, modification of the rennin-angiotensin system and management of lipid levels with statins-have been effective, but development of new strategies is essential if the ever-increasing burden of this disease is to be minimized. Peroxisome proliferator-activated receptors (PPAR) are members of the nuclear hormone receptor superfamily of ligand- activated transcription factors. PPAR-γ is the key regulator of lipid metabolism and energy balance implicated in the development of insulin resistance. The identification of putative natural and synthetic ligands and activators of PPAR-γ has helped to unravel the molecular basis of its function, including molecular details regarding ligand binding, conformational changes of the receptor and cofactor binding leading to the emergence of the concept of selective PPAR-γ modulators .No satisfactory therapeutic option is currently available to treat patients with nephropathy except for fewer agents like angiotensin converting enzyme inhibitors, angiotensin AT1 receptor blockers and few antioxidants, which have been shown to improve the function of diabetic kidney to some extent. Thus, tremendous efforts are being made to explore promising therapeutic interventions to treat diabetic nephropathy. This review discussed various presently employed and recently developed pharmacological interventions to treat diabetic nephropathy and to improve the function of diabetic kidney. In addition, the recently identified potential target sites involved in the pathogenesis of diabetic nephropathy have been delineated.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
部分PPAR γ激动剂是预防糖尿病肾脏异常的合理治疗策略吗
糖尿病可能是最重要的代谢性疾病,被广泛认为是导致死亡和残疾的主要原因之一。多达三分之一的糖尿病患者因糖尿病肾病而遭受终末期肾功能衰竭。延缓糖尿病肾病进展的策略-包括控制血糖和血压,修改肾素-血管紧张素系统和使用他汀类药物控制脂质水平-已经有效,但如果要将这种疾病日益增加的负担降至最低,开发新的策略是必不可少的。过氧化物酶体增殖体激活受体(PPAR)是核激素受体超家族的成员,是配体激活转录因子。PPAR-γ是参与胰岛素抵抗发展的脂质代谢和能量平衡的关键调节因子。对PPAR-γ的天然和合成配体和激活剂的鉴定有助于揭示其功能的分子基础,包括配体结合的分子细节,受体的构象变化和辅因子结合,导致选择性PPAR-γ调节剂的概念出现。目前,除了血管紧张素转换酶抑制剂等较少的药物外,没有令人满意的治疗方案可用于治疗肾病患者。血管紧张素AT1受体阻滞剂和少量抗氧化剂,已被证明在一定程度上改善糖尿病肾脏功能。因此,人们正在努力探索治疗糖尿病肾病的有前景的治疗干预措施。这篇综述讨论了各种目前使用的和最近开发的药物干预来治疗糖尿病肾病和改善糖尿病肾脏功能。此外,最近发现的潜在靶点参与糖尿病肾病的发病机制已经划定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Extemporaneous preparation as the last resort for drug shortage during covid-19 pandemic-lessons learned A unique combination of Alchornea cordifolia and Pterocarpus santalinoides in the management of multi-drug resistant diarrhoegenic bacterial infection. A review on: Soil microbes effect on human health. Could covid-19 virus be airborne? Pros and Challenges to Pharmacists in Prescribing Practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1